maleimide has been researched along with Cancer of Prostate in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kimura, H; Matsuoka, D; Ono, M; Saji, H; Shimizu, Y; Watanabe, H | 1 |
Damani, P; Danishefsky, SJ; Lee, D; Livingston, PO; Ouerfelli, O; Ragupathi, G; Spassova, MK; Wan, Q; Yang, G; Zhu, J | 1 |
Bak, P; Chen, J; Irvine, DJ; Stephan, MT; Stephan, SB | 1 |
Albrecht, H; Burke, PA; DeNardo, GL; DeNardo, SJ; Gregg, JP; Natarajan, A; O'Donnell, RT; Richman, CM; Yuan, A | 1 |
4 other study(ies) available for maleimide and Cancer of Prostate
Article | Year |
---|---|
Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
Topics: Animals; Cell Line, Tumor; Fluorescent Dyes; Humans; Iodine Radioisotopes; Male; Maleimides; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Succinimides; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous; Urea | 2017 |
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.
Topics: Animals; Antibody Formation; Antigens, Tumor-Associated, Carbohydrate; Binding Sites, Antibody; Breast Neoplasms; Cancer Vaccines; Cell Line, Tumor; Female; Hemocyanins; Humans; Male; Maleimides; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Vaccines, Synthetic | 2009 |
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.
Topics: Animals; Cells, Cultured; Drug Delivery Systems; Immunologic Factors; Immunological Synapses; Immunotherapy; Male; Maleimides; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nanoparticles; Prostate; Prostatic Neoplasms; Sulfhydryl Compounds; T-Lymphocytes | 2012 |
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antigens; Antigens, Neoplasm; Bone Marrow; Cathepsins; Combined Modality Therapy; Electrophoresis, Polyacrylamide Gel; Epitopes; Glycoproteins; Humans; Immunohistochemistry; Male; Maleimides; Maximum Tolerated Dose; Models, Chemical; Mucin-1; Mucins; Neoplasm Metastasis; Paclitaxel; Peptide Library; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Protein Binding; Radioimmunotherapy; Radiometry; Yttrium Radioisotopes | 2005 |